Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects

NCT05087069 | Completed Phase 1

• 1 other identifier: BV100-02
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

Safety and tolerability and Pharmacokinetics of multiple doses of BV100 in healthy volunteers

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (1)

• To investigate the safety and tolerability of increasing multiple intravenous doses of BV100

  Incidence of treatment-emergent adverse events (TEAEs)

  21 Days

Secondary Outcomes (2)

• To characterize the pharmacokinetic profile of rifabutin

  11 Days

• To characterize the plasma concentration of rifabutin

  11 Days

Study Arms (2)

BV100

EXPERIMENTAL

BV100 intravenous infusion

Drug: BV100

Placebo

PLACEBO COMPARATOR

Saline intravenous infusion

Drug: Placebo

Interventions

BV100 DRUG

Rifabutin for Infusion

BV100

Placebo DRUG

Saline intravenous infusion

Placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject must be 18 to 55 years of age inclusive at the time of signing the informed consent.
• Subjects who are healthy as determined by the Investigator based on medical evaluation including medical history, physical and neurological examination, vital signs, ECG, and clinical laboratory tests at screening and on Day -1.
• Subjects are able to have an intravenous line placed.
• Body weight of at least 50 kg and BMI within the range of 19 to 30 kg/m2 (inclusive) at screening examination.
• Male subjects will be included in the trial.
• Subjects must agree to the following from the time of the first dose until 3 months after the follow-up visit:
• use two acceptable methods of birth control with a female partner of child bearing potential (barrier method combined with an additional highly effective contraceptive method). Barrier methods of contraception include condom or occlusive cap (diaphragm or cervical/vault caps). Highly effective contraception is defined in accordance with the Clinical Trial Facilitation Group (CTFG 2020 ) guidance and includes the following methods: hormonal implants, injectables, hormonal intrauterine device, combined hormonal contraceptives, sexual abstinence and vasectomised sexual partner. For details refer to Appendix 2.
• refrain from donating sperm.
• Prior to any clinical trial specific procedure the subject provided written informed consent. Subjects must be able to read, write, and fully understand the German language.
• The subject is a non-smoker, former smoker (\<10 pack year smoking history) or former user of nicotine containing products or stable non-smoker for at least 3 months before the first study drug administration. Subjects should also have abstained from use of e-cigarettes for at least 3 months before first study drug administration.

You may not qualify if:

• History of clinically relevant disease of any organ system that may interfere with the objectives of the trial or provide a risk to the health of the subject.
• Known or suspected history of hypersensitivity to rifabutin or excipients or to drugs of a similar chemical class including rifampicin, rifapentine, rifaximin; history of allergic reactions leading to hospitalisation or any other allergic conditions (including drug allergies, asthma, eczema, anaphylactic reactions but excluding untreated, asymptomatic, seasonal allergies) which the Investigator considers may affect the safety of the subject and/or outcome of the trial.
• History of antibiotic associated diarrhoea within the last year.
• History of epilepsy, other neurological disorders, or neuropsychiatric conditions.
• Subjects with ECG abnormalities (history, or evidence of second-degree heart block of Mobitz type II, third degree heart block, or any abnormality considered relevant by the Investigator), QTcF \> 450 ms, PR \> 210 ms, or QRS duration \> 115 ms.
• Glomerular Filtration Rate (GFR) \< 80 mL/min/1.73m2 as calculated by the Chronic Kidney Disease Epidemiology Collaboration formula.
• Screening values other than AST, ALT, ALP, creatinine, for haematology, clinical chemistry, or urinalysis must not exceed the reference range. Minor deviations from normal are allowed, if they are not clinically significant.
• History of symptomatic, chronic or recurrent infection (e.g. nausea, vomiting, diarrhoea, infection with fever) or any viral (including symptomatic herpes zoster), bacterial (including upper respiratory infection), fungal (non-cutaneous) or parasitic infection within 30 days prior to admission to the clinical unit.
• Evidence of COVID-19 signs or symptoms, exposure to infected person or confirmed COVID-19 infection within the last 2 weeks.
• Subjects who have received any prescribed systemic or topical medication within 4 weeks of the dose administration or within 5 times the half-life, whichever is longer, except for the occasional use of paracetamol (up to 2 g/day).
• Subjects who have used any non-prescribed systemic or topical medication (including dietary supplements, natural and herbal remedies) or megadose vitamins (i.e. 20 to 600 times the recommended daily supplement dose) within 7 days of the dose administration, unless in the opinion of the Investigator the medication will not interfere with the trial procedures or compromise safety.
• Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the first dose administration.
• Regular use of any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit.
• Administration of live, attenuated, replication-competent vaccine(s), including vector-based or mRNA COVID-19 vaccine(s), within 1 month prior to screening or plans to receive such vaccines during the trial.
• Subjects who have participated in a clinical trial involving administration of an investigational drug (new chemical entity) within the following time period prior to the dosing day in the current trial: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).

Sponsors & Collaborators

• BioVersys SAS: lead
• Nuvisan GmbH: collaborator

Study Sites (1)

Nuvisan GmbH

Neu-Ulm, 89231, Germany

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 9, 2021
• First Posted: October 21, 2021
• Study Start: October 8, 2021
• Primary Completion: April 8, 2022
• Study Completion: January 12, 2023
• Last Updated: January 17, 2023

Record last verified: 2022-06

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)